摘要
目的 观察 β受体阻滞剂美托洛尔对慢性心力衰竭 (CHF)远期预后的影响。 方法 选择CHF患者 72例随机分为对照组 2 9例和观察组 4 3例 ,对照组采用综合疗法 ,观察组在综合治疗的基础上加美托洛尔 12 .5～ 5 0mg ,2 /d。在治疗前和观察期二年时分别对心功能 (NYHA) 2～ 3级患者作踏车负荷实验 ,记录患者所能耐受的最大运动功率和运动持续时间。结果 二年期间 ,对照组和观察组因心力衰竭加重再住院率分别为 82 .76 %和 2 5 .5 8% (P <0 .0 0 5 ) ,病死率分别为 31.0 3%和 9.0 3% (P <0 .0 2 5 ) ;与治疗前相比 ,观察组心功能 (NYHA分级 )、最大运动功率、运动持续时间均明显改善 (P <0 .0 0 1) ,而对照组无明显改善。
Objective To investigate the long term effect of Betabloc on the patients with chronic heart failure(CHF). Methods 72 CHF patients were divided into treatment group(43 cases) and control group(29 cases) randomly.The general therapy was given to the control group.Betaloc (12.5～25.0mg) was added to the treatment group plus general therapy.The pedal stress test performed in the CHF patients with NYHA class 2～3 prior to and at the end of 2-year treatment.The maximum motion quantity (Mq max) and the motion continuance time (MCT) were recored. Results The rehospitalization rate was 82.76% in control group and 25.8% in treatment group (P<0.005).The mortality rate was 31.03% in control group and 9.30% in treatment group (P<0.025) with 2 years.After 2 years,the heart function (NYHA),Mq max and MCT improved obviously in the treatment group (P<0.001,respectively) but did not change significantly in control group. Conclusion The long-term prognosis could be improved by Betaloc in CHF patients.
出处
《中国心血管病研究》
CAS
2004年第7期524-526,共3页
Chinese Journal of Cardiovascular Research
